Name: Utvärdering av en ulcerös koloproktit-kolorektal cancer (UC-CRC) modell och effekten av Liujunzi Decoction (LJZD)
Uploaded: 2023-10-13T12:50:00
Description: Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

evaluation of an ulcerative coloproctitis-colorectal cancer (uc-crc) model and efficacy of liujunzi decoction (ljzd)

Liujunzi avkok: En effektiv behandling för att förebygga UC-CRC

Colorectal cancer (CRC) is a common gastrointestinal malignancy, the third most common malignancy, and the second most common cause of death in the world, accounting for 10% of the global cancer incidence and 9.4% of the total cancer-related death1,2. Genetic factors, chronic inflammation, high-fat diet, diabetes, and abnormal intestinal flora are risk factors for CRC3,4. Among them, inflammatory bowel disease, especially ulcerative coloproctitis (UC), is a clear risk factor for CRC5,6. UC-associated CRC (UC-CRC) is a transition process of inflammation, atypical hyperplasia, and cancer based on chronic inflammation of the colorectum, which is different from the typical adenoma-adenocarcinoma development model of CRC7,8. Compared with the general population, the risk of CRC is approximately 10-40 times higher in patients with inflammatory bowel disease9.
Currently, surgery is still the standard treatment for CRC, and depending on the location and stage of the tumor, radiation therapy, systemic drug therapy, or a combination of both are possible10. Although these traditional treatment modalities have made great progress, due to the high heterogeneity and recurrence rate of CRC, the prognosis is poor, and the treatment effect is not ideal11,12. Therefore, early detection, early diagnosis, and comprehensive treatment are key to improving the survival rate of CRC patients, and it is particularly important to pay attention to the transformation of UC to CRC. Over the years, traditional Chinese medicine (TCM) has attracted much attention in the treatment of UC-CRC or chronic gastritis due to its limited side effects and significant efficacy. Based on dialectical treatment, famous Chinese medicine practitioners of various generations have created a large number of classic prescriptions, such as Huangqi Jianzhong decoction13, Sijunzi decoction14, and Sishen pill15.
Liujunzi decoction (LJZD) originated from the works of Yi Xue Zheng Zhuan compiled in the Ming Dynasty and is a classic prescription in TCM16. As shown in Table 1, LJZD consists of six traditional herbs, including Codonopsis pilosula (Franch.) Nannf. (Dangshen), Poria cocos (Schw.) Wolf (Fuling), Atractylodes macrocephala Koidz. (Baizhu), Glycyrrhiza uralensis Fisch. (Gancao), Citrus reticulata Blanco (Chenpi) and Pinellia ternata (Thunb.) Breit (Banxia), which has the effect of replenishing qi and strengthening the spleen, drying dampness, and resolving phlegm. In modern clinical practice, it is often used to treat chronic gastritis, gastric ulcers, and duodenal ulcers. Modern pharmacological research has shown that LJZD and modified LJZD have high application value in the adjuvant treatment of UC and digestive tract cancer17,18,19.
At present, there are many ways to construct UC-CRC mouse models, but the azoxymethane (AOM)/dextran sulfate sodium (DSS) induced mouse model is the most widely used UC-CRC model; the clinical symptoms, morphological, and pathological observations have proved that the model is very similar to human UC-CRC20,21. The basic principle is to first induce carcinogenesis with chemical carcinogen AOM and then continuously expose mice to the inflammatory stimulation environment of DSS to simulate the continuous damage and repair of intestinal mucosal epithelium, thereby constructing a UC-CRC mouse model22. The aim of this study is to establish a mouse model of UC-CRC by intraperitoneal injection of AOM and cyclic stimulation of DSS in the short term and to evaluate the effect of the drug and the molecular mechanism of LJZD on UC-CRC in order to provide a scientific basis for the treatment of UC-CRC.

Författare i fokus: Liujunzi avkok som en traditionell kinesisk behandling för koloproktitcancer

Etablering av koloproktit cancermodell hos möss och utvärdering av terapeutisk effekt av kinesisk medicin

This study was on the prevention and treatment of coloproctitis cancer with traditional Chinese medicine. We aim to establish a mouse model for coloproctitis cancer and evaluate traditional Chinese medicine indicators. We confirmed that the Chinese medicine Liujunzi decoction is a effective treatment for coloproctitis cancer prevention.In the future, we will work to identify more sensitive biomarkers for colon and rectal cancer and screen Liujunzi decoction for therapeutic targets.

Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

Utvärdering av en ulcerös koloproktit-kolorektal cancer (UC-CRC) modell och effekten av Liujunzi Decoction (LJZD)

Börja med att etablera UC-CRC-musmodellen och administrera den förberedda LJZD- och 5-ASA-lösningen till respektive grupp. Efter läkemedelsbehandlingen, övervaka mössens vikt dagligen från början av adaptiv utfodring till slutet av läkemedelsbehandlingen. Observera och dokumentera noggrant avföringskonsistensen hos varje experimentmus, kategorisera den som normal, lös avföring eller vattnig diarré.Dokumentera noggrant all fekal blödning som observerats hos försöksdjuren och kategorisera den som ingen blödning, minimal blödning eller synligt blod i avföringen. För att separera den kolorektala vävnaden, håll de avlivade mössen i en kryogen anatomisk miljö. Säkra mössen i ryggläge.Trimma det nedre bukhåret med en sax och sterilisera området med etanol. Använd en ögonlockstång och ta försiktigt tag i skärningspunkten mellan de två lårrötterna och bukens mittlinje. Använd sedan en sax för att skapa ett ett till 1,5 centimeter långt tvärsnitt.Utför ett längsgående snitt längs bukens medianlinje, med början från mittpunkten av det tvärgående snittet till xiphoidprocessen. Lossa försiktigt de perikolorektala vävnaderna i riktning mot anus, separera kolorektum från den omgivande vävnaden. Tryck försiktigt åt sidan bukhuden för att helt exponera kolorektumet.Använd en ögonlockstång för att dra ut kolorektum från bukhålan och dela den från anus till blindtarmen. Bevara de insamlade kolorektala vävnaderna i saltlösning vid fyra grader Celsius. UC-CRC-modellgruppen hade en signifikant viktminskning jämfört med kontrollgruppen, vilket lindrades av LJZD-behandling.LJZD-behandling förbättrade sjukdomsaktivitetsindex jämfört med UC-CRC-modellgruppen.

Research

JoVE Journal

Medicine

Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer (UC-CRC) Model and Efficacy of Liujunzi Decoction (LJZD)

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Colorectal cancer (CRC) is a common malignancy of the digestive system and has become the third most common malignancy worldwide and the second leading ...